
Brian R Lane MD
Professor at Michigan State University College of Human Medicine and Urologic Oncology Research Director at Corewell Health West
Join to View Full Profile
1900 Wealthy St SE Ste 100Grand Rapids, MI 49506
Phone+1 616-267-7333
Dr. Lane is on Doximity
As a Doximity member you'll join over two million verified healthcare professionals in a private, secure network.
- Gain access to free telehealth tools, such as our “call shielding” and one-way patient texting.
- Connect with colleagues in the same hospital or clinic.
- Read the latest clinical news, personalized to your specialty.
Summary
- Brian Lane, MD is a urologist based in Grand Rapids, MI specializing in urologic oncology and minimally invasive urologic surgery. He completed his residency in Urology at the Cleveland Clinic Foundation and is an alum of the University of Michigan Medical School. Dr. Lane has conducted clinical trials including "TAP Versus Thoracic Epidural in Major Abdominal Resections" and "TXA Study in Major Oncologic Surgery." He is recognized for his academic contributions having published various papers in reputable medical journals such as BJU International and Nature Reviews Urology. Dr. Lane was awarded the CMS Meaningful Use Stage 1 Certification from EpicCare Ambulatory EMR, Epic Systems Corporation in 2012 and is a fellow of the American College of Surgeons.
Education & Training
- Cleveland Clinic FoundationResidency, Urology, 2002 - 2008
- University of Michigan Medical SchoolClass of 2002
Certifications & Licensure
- MI State Medical License 2009 - 2025
- OH State Medical License 2002 - 2022
- American Board of Urology Urology
Awards, Honors, & Recognition
- CMS Meaningful Use Stage 1 Certification EpicCare Ambulatory EMR, Epic Systems Corporation, 2012
- Fellow (FACS) American College of Surgeons
Clinical Trials
- TXA Study in Major Oncologic Surgery Start of enrollment: 2012 Jun 12
- TAP Versus Thoracic Epidural in Major Abdominal Resections Start of enrollment: 2013 Dec 03
Publications & Presentations
PubMed
- Durability of Active Surveillance for Localized Renal Masses: 3-year Outcomes in the Michigan Urological Surgery Improvement Collaborative.Yuzhi Wang, Samantha Wilder, Monica Van Til, Mackenzie Gammons, Mahin Mirza
European Urology Open Science. 2025-05-01 - The use of nephron-sparing intervention does not appear to be compromised after a period of active surveillance for patients with cT1 renal masses.Michael Wang, Aaron Wilke, Samuel Goorman, Andrew McElroy, Jack Vercnocke
Urologic Oncology. 2025-04-01 - 1 citationsImpact of Gene Expression Classifier Testing on Adjuvant Treatment Following Radical Prostatectomy: The G-MINOR Prospective Randomized Cluster-crossover Trial.Todd M Morgan, Stephanie Daignault-Newton, Daniel E Spratt, Rodney L Dunn, Udit Singhal
European Urology. 2025-02-01
Journal Articles
- Assessment of Volume Preservation Performed Before or After Partial Nephrectomy Accurately Predicts Postoperative Renal Function: Results from a Prospective Multicente...Alexander Kutikov, Robert G Uzzo, Brian R Lane, Urologic Oncology
- Functional Duration of Closure Systems Used in Partial NephrectomyBrian Lane, MD, The Journal of Urology
Press Mentions
- In and Out Surgeries Become the Norm During PandemicOctober 29th, 2021
- Eligibility and Radiologic Assessment for Adjuvant Clinical Trials in Kidney CancerNovember 21st, 2019
- PCa Grade Group Better Predicts Pathologic Outcomes, RecurrenceFebruary 14th, 2019
- Join now to see all
Professional Memberships
- Member
Other Languages
- Spanish
Viewing the full profile is available to verified healthcare professionals only.
Find your profile and take control of your online presence: